Pharma-Grade Cannabis Could Hit Walgreens & CVS—But Can The Industry Survive The FDA?
As the formal review process for rescheduling cannabis unfolds, industry players are closely watching its potential to transform the sector. With the DEA hearing delayed until early 2025 and a possible Trump presidency adding uncertainty, cannabis …